Literature DB >> 3831997

Biological characterization of human bone tumors. VII. Detection of malignancy in a giant cell tumor of bone by flow cytometric DNA-analysis.

W Mellin, A Roessner, E Grundmann, B Wörmann, W Hiddemann, M Immenkamp.   

Abstract

The biological behavior of giant cell tumors of bone often cannot be definitively evaluated by light and electron microscopical criteria. As DNA aneuploidy was found to be a highly sensitive marker of malignant cells, we have analyzed this descriptive parameter in 4 giant cell tumors of bone by flow cytometry. Three of the four cases were non-metastasizing giant cell tumors, the fourth was a clinically malignant neoplasm presenting extensive visceral metastases four years after first diagnosis. Neither light- nor electron microscopical findings provided unequivocal criteria for defining the biological dignity of the four tumors. DNA aneuploidies were identified in the metastasizing case only, whereas the three clinically benign tumors showed a unimodal euploid DNA distribution. Thus flow cytometric DNA analysis is an additional diagnostic tool for the detection of malignancy in giant cell tumors of bone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3831997     DOI: 10.1016/S0344-0338(85)80040-6

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Histiocytic differentiation in benign and malignant bone tumors.

Authors:  A Meyer; T Steinmeier; T Löning; H J Radzun; G Delling
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Improved grading of bone tumors with the monoclonal antibody Ki-67.

Authors:  E Vollmer; A Roessner; J Gerdes; W Mellin; H Stein; S Chong-Schachel; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Recurrent pulmonary metastases from benign giant cell tumors of the bone: report of two cases and analysis of nuclear DNA content by flow cytometry.

Authors:  I Takanami; T Imamura; N Morota; S Kodaira
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.